Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Symptoms and General Pathology

Uterine Cervical Neoplasms

Recurrence

Carcinoma

Adenocarcinoma

Carcinoma, Squamous Cell

Carcinoma, Adenosquamous

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

All Drugs and Chemicals

Anti-Infective Agents

Fluorides

Fluorodeoxyglucose F18

Deoxyglucose

Radiopharmaceuticals

Antimetabolites

Antiviral Agents

Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks.

Computed Tomography

Diffusion Weighted Imaging

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Fludeoxyglucose F-18

Magnetic Resonance Spectroscopic Imaging

Positron Emission Tomography

Simon Lo

This trial studies magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging in predictive treatment response in patients with stage IB-IVA cervical cancer. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. PET is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Comparing results of diagnostic procedures, such as MRI and PET, done before, during and after radiation and chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

OUTLINE:

Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo dynamic contrast-enhanced (DCE) MRI, diffusion-weighted (DW) MRI, and magnetic resonance (MR) spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and fludeoxyglucose F 18 (FDG) PET/computed tomography (CT) at baseline, 2-2.5 weeks, and 4-5 weeks.

After completion of study, patients are followed up at least every 3-6 months for 5 years.

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix

Clinical/pelvic examination, pap smear, other standard of care investigations as indicated by clinical findings.

Hazard ratios will be calculated. Predictive power of the heterogeneity metrics will be compared and ranked with Federation of Gynecology and Obstetrics stage, lymph node status, histology, hemoglobin level, and tumor anatomic volumes. Multivariate predictive algorithms will be derived by synergizing the predictive power of imaging metrics and clinical prognosticators for clinical translation.

National Cancer Institute (NCI)

National Institutes of Health (NIH)

University of Washington

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer	NCT01992861	Cervical Adenoc... Cervical Adenos... Cervical Squamo... Cervical Undiff... Recurrent Cervi... Stage IB2 Cervi... Stage II Cervic... Stage IIA Cervi... Stage IIB Cervi... Stage III Cervi... Stage IIIA Cerv... Stage IIIB Cerv... Stage IVA Cervi...	Computed Tomogr... Diffusion Weigh... Dynamic Contras... Fludeoxyglucose... Magnetic Resona... Positron Emissi...	18 Years -	University of Washington
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer	NCT01992861	Cervical Adenoc... Cervical Adenos... Cervical Squamo... Cervical Undiff... Recurrent Cervi... Stage IB2 Cervi... Stage II Cervic... Stage IIA Cervi... Stage IIB Cervi... Stage III Cervi... Stage IIIA Cerv... Stage IIIB Cerv... Stage IVA Cervi...	Computed Tomogr... Diffusion Weigh... Dynamic Contras... Fludeoxyglucose... Magnetic Resona... Positron Emissi...	18 Years -	University of Washington

Spots Global Cancer Trial Database for cervical undifferentiated carcinoma